Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients(◆)

David R. Nelson, Stefan Zeuzem, Pietro Andreone, Peter Ferenci, Robert Herring, Donald M. Jensen, Patrick Marcellin, Paul J. Pockríos, Maribel Rodríguez-Torres, Lorenzo Rossaro, Vinod K. Rustgi, Thomas Sepe, Mark Sulkowski, Isaac R. Thomason, Eric M. Yoshida, Anna Chan, George Hill

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Introduction. Balapiravir (R1626, RG1626) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). This phase 2, double-blind international trial evaluated the optimal treatment regimen of balapiravir plus peginterferon alfa-2a (40KD)/ribavirin. Material and methods. Treatment-naive genotype 1 patients (N = 516) were randomized to one of seven treatment groups in which they received balapiravir 500, 1,000, or 1,500 mg twice daily, peginterferon alfa- 2a (40KD) 180 or 90 μg/week and ribavirin 1,000/1,200 mg/day or peginterferon alfa-2a (40KD)/ribavirin. The planned treatment duration with balapiravir was reduced from 24 to 12 weeks due to safety concerns. Results. The percentage of patients with undetectable HCV RNA was consistently higher in all balapiravir groups from week 2 to 12. However, high rates of dose modifications and discontinuations of one/all study drugs compromised the efficacy assessment and resulted in similar sustained virological response rates in the balapiravir groups (range 32-50%) and the peginterferon alfa-2a (40KD)/ribavirin group (43%). Balapiravir was discontinued for safety reasons in 28-36% of patients (most often for lymphopenia) and the percentage of patients with serious adverse events (especially hematological, infection, ocular events) was dose related. Serious hematological adverse events (particularly neutropenia, lymphopenia) were more common in balapiravir recipients. Two deaths in the balapiravir/peginterferon alfa-2a/ribavirin combination groups were considered possibly related to study medication. Conclusion. Further development of balapiravir for the treatment of chronic hepatitis C has been halted because of the unacceptable benefit to risk ratio revealed in this study (www.ClinicalTrials.gov NCT 00517439).

Original languageEnglish (US)
Pages (from-to)15-31
Number of pages17
JournalAnnals of Hepatology
Volume11
Issue number1
StatePublished - 2012

Fingerprint

balapiravir
Ribavirin
Hepatitis C
Genotype
Lymphopenia
4'-azidocytidine
Hepacivirus
peginterferon alfa-2a
RNA Replicase
Therapeutics
Safety
Eye Infections

Keywords

  • Chronic hepatitis C
  • Safety
  • SVR

ASJC Scopus subject areas

  • Hepatology

Cite this

Nelson, D. R., Zeuzem, S., Andreone, P., Ferenci, P., Herring, R., Jensen, D. M., ... Hill, G. (2012). Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients(◆). Annals of Hepatology, 11(1), 15-31.

Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients(◆). / Nelson, David R.; Zeuzem, Stefan; Andreone, Pietro; Ferenci, Peter; Herring, Robert; Jensen, Donald M.; Marcellin, Patrick; Pockríos, Paul J.; Rodríguez-Torres, Maribel; Rossaro, Lorenzo; Rustgi, Vinod K.; Sepe, Thomas; Sulkowski, Mark; Thomason, Isaac R.; Yoshida, Eric M.; Chan, Anna; Hill, George.

In: Annals of Hepatology, Vol. 11, No. 1, 2012, p. 15-31.

Research output: Contribution to journalArticle

Nelson, DR, Zeuzem, S, Andreone, P, Ferenci, P, Herring, R, Jensen, DM, Marcellin, P, Pockríos, PJ, Rodríguez-Torres, M, Rossaro, L, Rustgi, VK, Sepe, T, Sulkowski, M, Thomason, IR, Yoshida, EM, Chan, A & Hill, G 2012, 'Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients(◆)', Annals of Hepatology, vol. 11, no. 1, pp. 15-31.
Nelson DR, Zeuzem S, Andreone P, Ferenci P, Herring R, Jensen DM et al. Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients(◆). Annals of Hepatology. 2012;11(1):15-31.
Nelson, David R. ; Zeuzem, Stefan ; Andreone, Pietro ; Ferenci, Peter ; Herring, Robert ; Jensen, Donald M. ; Marcellin, Patrick ; Pockríos, Paul J. ; Rodríguez-Torres, Maribel ; Rossaro, Lorenzo ; Rustgi, Vinod K. ; Sepe, Thomas ; Sulkowski, Mark ; Thomason, Isaac R. ; Yoshida, Eric M. ; Chan, Anna ; Hill, George. / Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients(◆). In: Annals of Hepatology. 2012 ; Vol. 11, No. 1. pp. 15-31.
@article{ad1954fef5f54430b7aba524b6346532,
title = "Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients(◆)",
abstract = "Introduction. Balapiravir (R1626, RG1626) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). This phase 2, double-blind international trial evaluated the optimal treatment regimen of balapiravir plus peginterferon alfa-2a (40KD)/ribavirin. Material and methods. Treatment-naive genotype 1 patients (N = 516) were randomized to one of seven treatment groups in which they received balapiravir 500, 1,000, or 1,500 mg twice daily, peginterferon alfa- 2a (40KD) 180 or 90 μg/week and ribavirin 1,000/1,200 mg/day or peginterferon alfa-2a (40KD)/ribavirin. The planned treatment duration with balapiravir was reduced from 24 to 12 weeks due to safety concerns. Results. The percentage of patients with undetectable HCV RNA was consistently higher in all balapiravir groups from week 2 to 12. However, high rates of dose modifications and discontinuations of one/all study drugs compromised the efficacy assessment and resulted in similar sustained virological response rates in the balapiravir groups (range 32-50{\%}) and the peginterferon alfa-2a (40KD)/ribavirin group (43{\%}). Balapiravir was discontinued for safety reasons in 28-36{\%} of patients (most often for lymphopenia) and the percentage of patients with serious adverse events (especially hematological, infection, ocular events) was dose related. Serious hematological adverse events (particularly neutropenia, lymphopenia) were more common in balapiravir recipients. Two deaths in the balapiravir/peginterferon alfa-2a/ribavirin combination groups were considered possibly related to study medication. Conclusion. Further development of balapiravir for the treatment of chronic hepatitis C has been halted because of the unacceptable benefit to risk ratio revealed in this study (www.ClinicalTrials.gov NCT 00517439).",
keywords = "Chronic hepatitis C, Safety, SVR",
author = "Nelson, {David R.} and Stefan Zeuzem and Pietro Andreone and Peter Ferenci and Robert Herring and Jensen, {Donald M.} and Patrick Marcellin and Pockr{\'i}os, {Paul J.} and Maribel Rodr{\'i}guez-Torres and Lorenzo Rossaro and Rustgi, {Vinod K.} and Thomas Sepe and Mark Sulkowski and Thomason, {Isaac R.} and Yoshida, {Eric M.} and Anna Chan and George Hill",
year = "2012",
language = "English (US)",
volume = "11",
pages = "15--31",
journal = "Annals of Hepatology",
issn = "1665-2681",
publisher = "Mexican Association of Hepatology",
number = "1",

}

TY - JOUR

T1 - Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients(◆)

AU - Nelson, David R.

AU - Zeuzem, Stefan

AU - Andreone, Pietro

AU - Ferenci, Peter

AU - Herring, Robert

AU - Jensen, Donald M.

AU - Marcellin, Patrick

AU - Pockríos, Paul J.

AU - Rodríguez-Torres, Maribel

AU - Rossaro, Lorenzo

AU - Rustgi, Vinod K.

AU - Sepe, Thomas

AU - Sulkowski, Mark

AU - Thomason, Isaac R.

AU - Yoshida, Eric M.

AU - Chan, Anna

AU - Hill, George

PY - 2012

Y1 - 2012

N2 - Introduction. Balapiravir (R1626, RG1626) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). This phase 2, double-blind international trial evaluated the optimal treatment regimen of balapiravir plus peginterferon alfa-2a (40KD)/ribavirin. Material and methods. Treatment-naive genotype 1 patients (N = 516) were randomized to one of seven treatment groups in which they received balapiravir 500, 1,000, or 1,500 mg twice daily, peginterferon alfa- 2a (40KD) 180 or 90 μg/week and ribavirin 1,000/1,200 mg/day or peginterferon alfa-2a (40KD)/ribavirin. The planned treatment duration with balapiravir was reduced from 24 to 12 weeks due to safety concerns. Results. The percentage of patients with undetectable HCV RNA was consistently higher in all balapiravir groups from week 2 to 12. However, high rates of dose modifications and discontinuations of one/all study drugs compromised the efficacy assessment and resulted in similar sustained virological response rates in the balapiravir groups (range 32-50%) and the peginterferon alfa-2a (40KD)/ribavirin group (43%). Balapiravir was discontinued for safety reasons in 28-36% of patients (most often for lymphopenia) and the percentage of patients with serious adverse events (especially hematological, infection, ocular events) was dose related. Serious hematological adverse events (particularly neutropenia, lymphopenia) were more common in balapiravir recipients. Two deaths in the balapiravir/peginterferon alfa-2a/ribavirin combination groups were considered possibly related to study medication. Conclusion. Further development of balapiravir for the treatment of chronic hepatitis C has been halted because of the unacceptable benefit to risk ratio revealed in this study (www.ClinicalTrials.gov NCT 00517439).

AB - Introduction. Balapiravir (R1626, RG1626) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). This phase 2, double-blind international trial evaluated the optimal treatment regimen of balapiravir plus peginterferon alfa-2a (40KD)/ribavirin. Material and methods. Treatment-naive genotype 1 patients (N = 516) were randomized to one of seven treatment groups in which they received balapiravir 500, 1,000, or 1,500 mg twice daily, peginterferon alfa- 2a (40KD) 180 or 90 μg/week and ribavirin 1,000/1,200 mg/day or peginterferon alfa-2a (40KD)/ribavirin. The planned treatment duration with balapiravir was reduced from 24 to 12 weeks due to safety concerns. Results. The percentage of patients with undetectable HCV RNA was consistently higher in all balapiravir groups from week 2 to 12. However, high rates of dose modifications and discontinuations of one/all study drugs compromised the efficacy assessment and resulted in similar sustained virological response rates in the balapiravir groups (range 32-50%) and the peginterferon alfa-2a (40KD)/ribavirin group (43%). Balapiravir was discontinued for safety reasons in 28-36% of patients (most often for lymphopenia) and the percentage of patients with serious adverse events (especially hematological, infection, ocular events) was dose related. Serious hematological adverse events (particularly neutropenia, lymphopenia) were more common in balapiravir recipients. Two deaths in the balapiravir/peginterferon alfa-2a/ribavirin combination groups were considered possibly related to study medication. Conclusion. Further development of balapiravir for the treatment of chronic hepatitis C has been halted because of the unacceptable benefit to risk ratio revealed in this study (www.ClinicalTrials.gov NCT 00517439).

KW - Chronic hepatitis C

KW - Safety

KW - SVR

UR - http://www.scopus.com/inward/record.url?scp=83055197050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83055197050&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 15

EP - 31

JO - Annals of Hepatology

JF - Annals of Hepatology

SN - 1665-2681

IS - 1

ER -